Sotio Biotech, a Prague, Czech Republic-based clinical stage immuno-oncology company, secured €280m in funding.
PPF Group made the investment.
Led by Radek Spisek, Ph.D., CEO, the company intends to use the funds to advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023. The funding will be used to advance SOT101 through two multi-indication phase 2 clinical trials: The phase 2 AURELIO-03 study tests SOT101 as monotherapy in patients with melanoma, squamous skin carcinoma and kidney cancer, and a planned phase 2 AURELIO-04 study will evaluate the combination of SOT101 with a checkpoint inhibitor. This funding will also be used to advance three novel programs through phase 1:
- BOXR1030, the company’s lead CAR-T program for the treatment of various solid tumors expressing GPC3,
- SOT102, a novel ADC with a best-in-class potential for Claudin 18.2 targeting therapies, and
- to initiate a phase 1 study with its first IL-15 based immunocytokine using a PD-1 inhibitor as the targeting arm by the end of 2022.
The funding is contingent on the achievement of certain development and regulatory milestones.
FinSMEs
02/12/2021